{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:24:05Z","timestamp":1787642645052,"version":"build-2736575974"},"reference-count":38,"publisher":"Georg Thieme Verlag KG","issue":"07","funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["(2021-1-I2M-002"],"award-info":[{"award-number":["(2021-1-I2M-002"]}]},{"name":"National Key Program of Clinical Science","award":["WBYZ2011-873"],"award-info":[{"award-number":["WBYZ2011-873"]}]},{"name":"Beijing Natural Science Foundation","award":["7222137, 7182130, 7082079"],"award-info":[{"award-number":["7222137, 7182130, 7082079"]}]},{"name":"PUMCH Foundation","award":["2013-020"],"award-info":[{"award-number":["2013-020"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81370898, 30771026"],"award-info":[{"award-number":["81370898, 30771026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"China Diabetes Young Scientific Talent Research Project","award":["2020-N-01-10"],"award-info":[{"award-number":["2020-N-01-10"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aim\u2002To determine the antiobesity effect and safety of glucagon-like\n                    peptide-1 receptor agonist (GLP-1RA) including liraglutide, exenatide and\n                    semaglutide treatment in overweight\/obese patients without diabetes. The\n                    random-effect model was used to pool data extracted from included literatures.\n                    The weighted mean difference (WMD), odds ratio and 95% confidence\n                    interval (CI) were used to present the meta-analysis results (PROSPERO\n                    registration number: CRD 42020173199). The sources of intertrial heterogeneity,\n                    bias and the robustness of results were evaluated by subgroup analysis,\n                    sensitivity analysis and regression analysis, respectively. A total of 24 RCTs\n                    were recruited in the present analysis which included 5867 patients. The results\n                    showed that the treatment of overweight\/obese patients without diabetes\n                    with GLP-1RAs including liraglutide, exenatide and semaglutide significantly\n                    achieved greater weight loss than placebo [WMD=\u20135.39,\n                    95% CI (\u20136.82, \u20133.96)] and metformin\n                    [WMD=\u20135.46, 95% CI (\u20135.87, \u20135.05)]. The\n                    subgroup analysis showed that semaglutide displayed the most obvious antiobesity\n                    effect in terms of weight loss, the reduction of body mass index (BMI) and waist\n                    circumference (WC). However, GLP-1RAs treatments had more gastrointestinal\n                    adverse events (such as nausea and vomiting) than placebo and Met. The subgroup\n                    analysis also represented that semaglutide displayed the lowest risk of\n                    gastrointestinal adverse events among three kinds of GLP-1RAs. Our meta-analysis\n                    demonstrated that GLP-1RA had a superior antiobesity effect than\n                    placebo\/Met in overweight\/obese patients without diabetes in\n                    terms of body weight, BMI, and WC, especially for semaglutide, which had more\n                    obvious antiobesity effect and lower GI adverse events than liraglutide and\n                    exenatide.<\/jats:p>","DOI":"10.1055\/a-1844-1176","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:45:07Z","timestamp":1651797907000},"page":"458-471","source":"Crossref","is-referenced-by-count":52,"title":["The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in\n                    Overweight\/Obese Patients Without Diabetes: A Systematic Review and\n                    Meta-Analysis"],"prefix":"10.1055","volume":"54","author":[{"given":"Xiaonan","family":"Guo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Lyu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Pan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengying","family":"Gong","sequence":"additional","affiliation":[{"name":"Key Laboratory of Endocrinology of National Health Commission,\n                    Department of Endocrinology, Peking Union Medical College Hospital, Chinese\n                    Academy of Medical Sciences and Peking Union Medical College, Beijing,\n                    China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0889-8529(03)00071-9","article-title":"Obesity and type 2 diabetes","volume":"32","author":"C A Maggio","year":"2003","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1001\/jama.2020.12567","article-title":"Benefits and risks of bariatric surgery in adults: a review","volume":"324","author":"D E Arterburn","year":"2020","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013\n                    state-of-the-art","volume":"46","author":"M A Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"ref4","first-page":"161","article-title":"A role for GLP-1 in treating hyperphagia and obesity","author":"H J Grill","year":"2020","journal-title":"Endocrinology"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1753-0407.12198","article-title":"Weight loss effect of glucagon-like peptide-1 mimetics on\n                    obese\/overweight adults without diabetes: A systematic review and\n                    meta-analysis of randomized controlled trials","volume":"7","author":"F Zhang","year":"2015","journal-title":"J Diabetes"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/obr.12839","article-title":"Semaglutide as a promising antiobesity drug","volume":"20","author":"G A Christou","year":"2019","journal-title":"Obes Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for\n                    weight loss in patients with obesity: a randomised, double-blind, placebo and\n                    active controlled, dose-ranging, phase 2 trial","volume":"392","author":"P M O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive\n                    behavioral therapy on body weight in adults with overweight or obesity: The STEP\n                    3 randomized clinical trial","volume":"325","author":"T A Wadden","year":"2021","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss\n                    maintenance in adults with overweight or obesity: The STEP 4 randomized clinical\n                    trial","volume":"325","author":"D Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref10","first-page":"989","article-title":"Once-weekly semaglutide in adults with overweight or obesity. N Eng","volume":"384","author":"JP H Wilding","year":"2021","journal-title":"J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind,\n                    placebo-controlled study","volume":"374","author":"A Astrup","year":"2009","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-13-0797","article-title":"Short-term combined treatment with liraglutide and metformin leads to\n                    significant weight loss in obese women with polycystic ovary syndrome and\n                    previous poor response to metformin","volume":"170","author":"M Jensterle Sever","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e12624","DOI":"10.1111\/ijpo.12624","article-title":"A 6-month randomized, double-blind, placebo-controlled trial of weekly exenatide\n                    in adolescents with obesity","volume":"15","author":"D Weghuber","year":"2020","journal-title":"Pediatr Obes"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose\n                    tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"J Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1475-2840-11-64","article-title":"Effects of exenatide vs. metformin on endothelial function in obese patients\n                    with pre-diabetes: a randomized trial","volume":"11","author":"A S Kelly","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/dom.14224","article-title":"A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1\n                    receptor agonist in adolescents and young adults with hypothalamic obesity","volume":"3","author":"C L Roth","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on\n                    menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"K Elkind-Hirsch","year":"2008","journal-title":"J Clin EEndocrinol Metab"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF03401383","article-title":"A 12-week treatment with the long-acting glucagon-like peptide 1 receptor\n                    agonist liraglutide leads to significant weight loss in a subset of obese women\n                    with newly diagnosed polycystic ovary syndrome","volume":"14","author":"M Jensterle","year":"2015","journal-title":"Hormones"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13048-015-0161-3","article-title":"Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4\n                    inhibitor roflumilast is superior to metformin in weight loss in obese PCOS\n                    women: a pilot randomized study","volume":"8","author":"M Jensterle","year":"2015","journal-title":"J Ovarian Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or\n                    severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical\n                    trial","volume":"40","author":"A Blackman","year":"2016","journal-title":"Int J Obes"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdv.12629","article-title":"Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on\n                    psoriasis in glucose-tolerant patients\u2013a randomized placebo-controlled\n                    trial","volume":"9","author":"A Faurschou","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized\n                    clinical trial","volume":"20","author":"S Fr\u00f8ssing","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight\n                    Management","volume":"373","author":"X Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.obmed.2017.06.003","article-title":"Short term monotherapy with exenatide is superior to metformin in weight loss,\n                    improving insulin resistance and inflammation in Chinese\n                    overweight\/obese PCOS women","volume":"7","author":"S Zheng","year":"2017","journal-title":"Obes Med"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.orcp.2015.03.005","article-title":"Improvement in binge eating in non-diabetic obese individuals after 3 months of\n                    treatment with liraglutide \u2013 a pilot study","volume":"9","author":"S A Robert","year":"2015","journal-title":"Obes Res Clin Pract"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/cen.13454","article-title":"Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in\n                    overweight\/obese polycystic ovary syndrome","volume":"87","author":"X Liu","year":"2017","journal-title":"Clin Endocrinol"},{"key":"ref27","first-page":"35","article-title":"Short-term exenatide treatment leads to significant weight loss in a subset of\n                    obese women without diabetes","author":"J Dushay","year":"2012","journal-title":"Diabetes Care"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/ijo.2014.88","article-title":"Weight maintenance and additional weight loss with liraglutide after\n                    low-calorie-diet-induced weight loss: The SCALE maintenance randomized\n                    study","volume":"39","author":"T A Wadden","year":"2015","journal-title":"Int J Obes"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.2337\/dc13-0354","article-title":"Benefits of liraglutide treatment in overweight and obese older individuals with\n                    prediabetes","volume":"36","author":"S H Kim","year":"2013","journal-title":"Diabetes Care"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2\n                    diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Z Z Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijcard.2016.06.028","article-title":"Exenatide in obese or overweight patients without diabetes: A systematic review\n                    and meta-analyses of randomized controlled trials","volume":"219","author":"N Su","year":"2016","journal-title":"Int J Cardiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejim.2014.03.005","article-title":"Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes:\n                    differences and similarities","volume":"25","author":"A Lund","year":"2014","journal-title":"Eur J Intern Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(17)30412-6","article-title":"Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in\n                    patients with type 2 diabetes: a meta-analysis","volume":"6","author":"M A Bethel","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of\n                    gastric emptying in humans","volume":"60","author":"M A Nauck","year":"2011","journal-title":"Diabetes"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s40618-020-01348-9","article-title":"Liraglutide is an effective drug for the treatment of obesity also in real\n                    life","volume":"43","author":"E Piantanida","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"J M Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of\n                    eating, food preference and body weight in subjects with obesity","volume":"19","author":"J Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"108656","DOI":"10.1016\/j.diabres.2021.108656","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral\n                    semaglutide in patients with type 2 diabetes mellitus: aA systematic review and\n                    meta-analysis","volume":"172","author":"J Li","year":"2021","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1844-1176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T10:27:13Z","timestamp":1660127233000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1844-1176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":38,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2022,7,14]]},"published-print":{"date-parts":[[2022,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1844-1176","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,5]]},"published":{"date-parts":[[2022,5,5]]}}}